131 related articles for article (PubMed ID: 25052407)
1. FDG PET/CT imaging in prostate adenocarcinoma presenting as isolated brain metastases of unknown origin.
Erhamamcı S; Reyhan M; Alkan O
Rev Esp Med Nucl Imagen Mol; 2015; 34(2):146-7. PubMed ID: 25052407
[No Abstract] [Full Text] [Related]
2. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis of penile metastases of prostatic origin with 11C-Choline PET/CT.
Garcia JR; Aguilo JJ; Marco V; Valls E; Soler M; Lomeña F
Rev Esp Med Nucl Imagen Mol; 2012 Sep; 31(5):295-6. PubMed ID: 22682926
[No Abstract] [Full Text] [Related]
4. [Early cerebral metastasis of colonic adenocarcinoma].
Serantes Gómez A; Monturiol JM; Alcázar Montero JA; Jiménez Almonacid P; García Sabrido JL
Rev Esp Enferm Dig; 1996 Feb; 88(2):141-3. PubMed ID: 8664071
[TBL] [Abstract][Full Text] [Related]
5. Comparison of bone scintigraphy and 18F-FDG PET-CT in a prostate cancer patient with osteolytic bone metastases.
Ozcan Kara P; Kara T; Kara Gedik G; Sari O; Sahin O
Rev Esp Med Nucl; 2011; 30(2):94-6. PubMed ID: 21342722
[TBL] [Abstract][Full Text] [Related]
6. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation.
Oyama N; Akino H; Suzuki Y; Kanamaru H; Ishida H; Tanase K; Sadato N; Yonekura Y; Okada K
Nucl Med Commun; 2001 Sep; 22(9):963-9. PubMed ID: 11505204
[TBL] [Abstract][Full Text] [Related]
7. [18F]Fluorodeoxyglucose positron emission tomography surveillance of hepatic metastases from prostate cancer following radiofrequency ablation: a case report.
Ludwig V; Hopper OW; Martin WH; Kikkawa R; Delbeke D
Am Surg; 2003 Jul; 69(7):593-8. PubMed ID: 12889623
[TBL] [Abstract][Full Text] [Related]
8. FDG-PET imaging in duodenal cancer.
Watanabe N; Hayashi S; Kato H; Shimizu M; Kamisaki Y; Noguchi K; Kishida M; Matsunari I; Hisada K; Seto H
Ann Nucl Med; 2004 Jun; 18(4):351-3. PubMed ID: 15359930
[TBL] [Abstract][Full Text] [Related]
9. Incidental diagnosis of a PSA-negative prostate cancer by 18FDG PET/CT in a patient with hypopharyngeal cancer.
Bucerius J; Ahmadzadehfar H; Hortling N; Joe AY; Palmedo H; Biersack HJ
Prostate Cancer Prostatic Dis; 2007; 10(3):307-10. PubMed ID: 17353915
[TBL] [Abstract][Full Text] [Related]
10. Response of cerebral metastasis secondary to prostate cancer to primary androgen suppression.
Bhuva NJ; Ward D; Hughes R
BMJ Case Rep; 2010 Nov; 2010():. PubMed ID: 22789555
[TBL] [Abstract][Full Text] [Related]
11. Fluorodeoxyglucose positron emission tomography scan of prostate cancer bone metastases with flare reaction after endocrine therapy.
Shimizu N; Masuda H; Yamanaka H; Oriuchi N; Inoue T; Endo K
J Urol; 1999 Feb; 161(2):608-9. PubMed ID: 9915462
[No Abstract] [Full Text] [Related]
12. [Contribution of PET in the follow-up of cerebral metastases in non-small cell lung cancer. A clinical case valuation].
Ferrer Rebolleda J; Ortega de los Mártires F; Santos Cores J; Menéndez López A; Arribas Alpuente L; Almenar Medina S
Rev Esp Med Nucl; 2006; 25(2):107-12. PubMed ID: 16759617
[TBL] [Abstract][Full Text] [Related]
13. FDG PET/CT in a Case of Pure Ductal Adenocarcinoma of the Prostate With Osteolytic Metastases and Normal PSA Level.
Dong A; Lin X; Bai Y; Yang B; Xu S
Clin Nucl Med; 2023 Jul; 48(7):640-642. PubMed ID: 36976639
[TBL] [Abstract][Full Text] [Related]
14. Lung cancer and Rosai-Dorfman's disease. A clinicopathological study.
Lutterbach J; Henne K; Pagenstecher A; Böhm J
Strahlenther Onkol; 2003 Jul; 179(7):486-92. PubMed ID: 12835886
[TBL] [Abstract][Full Text] [Related]
15. A newly designed attachment device of multipurpose frame for neuronavigator. Technical note.
Singh AK; Okudera H; Kobayashi S; Osawa M; Tokushige K
Acta Neurochir (Wien); 1994; 129(1-2):97-9. PubMed ID: 7998505
[TBL] [Abstract][Full Text] [Related]
16. Multimodality imaging in biochemical recurrence of prostate cancer: utility of (18)F-NaF PET/CT in early detection of metastasis.
Desai B; Gross ME; Jadvar H
Rev Esp Med Nucl Imagen Mol; 2012; 31(4):231-2. PubMed ID: 22980132
[No Abstract] [Full Text] [Related]
17. Utility of low dose (18)F-FDG PET-CT in patients with suspected colorectal carcinoma recurrence in conventional diagnostic methods.
Ochoa-Figueroa MA; Uña-Gorospe J; Allende-Riera A; Cárdenas-Negro JC; Muñoz-Iglesias J; Cabello-García D; De Sequera-Rahola M; Martínez-Gimeno E
Rev Esp Med Nucl Imagen Mol; 2012 Sep; 31(5):249-56. PubMed ID: 23067526
[TBL] [Abstract][Full Text] [Related]
18. Prostatic adenocarcinoma presenting with metastatic frontal bone involvement and orbital invasion.
Patel V; Castell FA; Akinwunmi J; Francis I; Chandrasekharan L; Malhotra R
Orbit; 2010 Aug; 29(4):213-5. PubMed ID: 20812840
[TBL] [Abstract][Full Text] [Related]
19. [Reply to editorial comment on article "Usefulness of PET scans in diagnosing recurrent prostate cancer. Prostate with PSA level <5ng/ml"].
Rioja Zuazu J; Zudaire Bergera JJ; Richter JA; Berián Polo JM
Actas Urol Esp; 2010 Jan; 34(1):12-4. PubMed ID: 20223128
[No Abstract] [Full Text] [Related]
20. [Central neurocytoma of the right parietal and occipital lobe. Case report].
Liebert W; Szymaś J; Majewski T; Paprzycki W
Neurol Neurochir Pol; 1998; 32(1):191-9. PubMed ID: 9631391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
